戻る Agenda
Session 2: The Pitfalls and Promises of Real World Evidence in Evolving the Biosimilar Industry
Session Chair(s)
Mark Stewart, PHD
Vice President, Science Policy, Friends of Cancer Research, United States
Anna Welch, MA
Chief Editor, Biosimilar Development, Life Science Connect, United States
Learning Objective : At the conclusion of this session, participants should be able to:- Evaluate current best-practices and challenges in RWE collection, analysis, and promotion
- Assess evolving strategies for employing RWE in education
- Discuss the impact RWE can have on pre-approval clinical data and the treatment pathway
Speaker(s)
Jaclyn Bosco, MPH, FISPE
Vice President & General Manager, Global Head of Epidemiology & Scientific Strat, IQVIA, United States
Speaker
Nancy Lin, DRSC, MS
Senior Scientist, Epidemiology, Optum, United States
Speaker
Edward Li, PHARMD, MPH
Associate Director, HEOR & RWE, Sandoz, United States
Speakers
Gianluca Trifiro, MD, PHD
Scientific Lead, INSPIRE; Professor, Pharmacology, Diagnostics and Public Health, University of Verona, Italy
Speaker